Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, s...
Q2 2025
Dec 22, 2025
FY 2024
Apr 3, 2025
Q4 2024
Dec 30, 2024
Q2 2024
Jun 30, 2024
FY 2023
Mar 28, 2024